Physician profile
Vanraj Varu
NPI 1033188826
$1,306.39
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $230 · 2021: $236 · 2022: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $406.50 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $282.80 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $215.18 | 2019-2021 | |
| Abbvie INC. | $117.39 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.28 | 2021-2022 | |
| Lundbeck LLC | $37.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.65 | 2019-2020 | |
| Bausch Health US, LLC | $24.88 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.15 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.95 | 2022 | |
| Lilly USA, LLC | $12.64 | 2019 | |
| Alfasigma USA, INC. | $11.04 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanraj Varu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.